63758-12-3

Basic information

• Product Name: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE
• Synonyms: TIMTEC-BB SBB010128;AKOS BBS-00003080;2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE;2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULPHONYLCHLORIDE;2,3-DIHYDRO-BENZO[1,4]DIOXINE-6-SULFONYL CHLORIDE;1,4-BENZODIOXIN-6-SULFONYL CHLORIDE, 2,3-DIHYDRO-;BUTTPARK 95\50-61;CHEMBRDG-BB 4902369
• CAS NO: 63758-12-3
• Molecular Formula: C₈H₇ClO₄S
• Molecular Weight: 234.66
• Product Categories: SULFONYLHALIDE
• Mol File: 63758-12-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 66 °C
• Boiling Point: 344.2 °C at 760 mmHg
• Flash Point: 162 °C
• Appearance: /
• Density: 1.513 g/cm³
• Vapor Pressure: 0.000133mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Inert atmosphere,Room Temperature
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE(63758-12-3)
• EPA Substance Registry System: 2,3-DIHYDRO-1,4-BENZODIOXINE-6-SULFONYL CHLORIDE(63758-12-3)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34
• Safety Statements: 26-36/37/39-45-36/37
• RIDADR: 3261
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 63758-12-3(Hazardous Substances Data)

Usage

General Description

2,3-Dihydro-1,4-benzodioxine-6-sulfonyl chloride is a chemical compound often utilized in the field of organic chemistry. This chemical, known for its use as a reagent, plays a significant role in the formation of a variety of organic structures and compounds. As a sulfonamide-derived chemical, it mainly serves as a key component used in the chemical synthesis industry for the manufacture of various substances. However, it's crucial to handle and store this compound under appropriate conditions due to its reactivity and sensitivity, as non-compliance can lead to dangerous or undesirable reactions. Despite its potential risks, 2,3-Dihydro-1,4-benzodioxine-6-sulfonyl chloride remains a popular and valuable chemical tool in advanced chemical synthesis operations.

InChI:InChI=1/C8H7ClO4S/c9-14(10,11)6-1-2-7-8(5-6)13-4-3-12-7/h1-2,5H,3-4H2

Upstream product

• 274-09-9 Methylenedioxybenzene 
• 107-06-2 1,2-dichloro-ethane 
• 493-09-4 benzo-1,4-dioxane 

Downstream Products

• 252873-07-7 {(1S,2R)-1-Benzyl-3-[cyclopentyloxy-(2,3-dihydro-benzo[1,4]dioxine-6-sulfonyl)-amino]-2-hydroxy-propyl}-carbamic acid tert-butyl ester 
• 956467-57-5 (2S,5S)-1-{[3,4-bis(methyloxy)phenyl]sulfonyl}-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-2,5-dimethylpiperazine 
• 314260-32-7 C₁₅H₁₃NO₆S 

Relevant articles and documents

Sulfonamide inhibitors of aspartyl protease

The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical

alpha 1a adrenergic receptor antagonists

This invention relates to novel compounds, their synthesis and use as selective alpha 1a adrenergic receptor antagonists. One application of the compounds is in the treatment of benign prostatic hyperplasia. The compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Alpha IC adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha-1C adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hypertrophy. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha1C receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.